Transgenic Group Inc. (TSE: 2342)

About Transgenic Group Inc.

Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Investment Business. Within its Drug Discovery Support segment, the company offers a comprehensive array of services. These include the synthesis and analytical assessment of glycans (or sugar chains), alongside extensive non-clinical investigations crucial for pharmaceuticals, food products, cosmetics, and various chemical compounds. The firm conducts diverse safety evaluations for both food and pharmaceutical agents, and provides vital support for bioequivalence studies, encompassing clinical trials, pharmacokinetic measurements, and the compilation of clinical trial reports. Hospital support services are also part of its offerings. Furthermore, Trans Genic performs drug efficacy and pharmacological testing, provides strategic advisory services covering mergers & acquisitions, business restructuring, and succession planning, and undertakes contract manufacturing of items such as genetically engineered mice, antibodies, protein hypers, and expression cells. It also markets mouse models, associated products, and research reagents. Established in 1998, the company was initially known as Kumamoto Immunochemical Laboratories Inc. before rebranding as Trans Genic Inc. in April 2000. Its corporate headquarters are located in Fukuoka City, Japan.

ISIN

JP3635720000

Founded

1998

Listed since

Dec 10, 2002

Exchange

The Tokyo Stock Exchange

Currency

JPY